BioSpace: Biotech, Pharmaceutical and Clinical Research News
Deep Dive: PBM Reform. In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: pharmacy benefit managers. In this special …
News - BioSpace
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024.
BioSpace - BioSpace
July 31, 2024. ·. 2 min read. ·. BioSpace. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations …
About Us - BioSpace
About Us. BioSpace is the hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who …
All News - BioSpace
6 天之前 — Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control and Prevention, where his anti-vaccine views will …
Approvals - BioSpace
2024年11月14日 — Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population. Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less …
China - BioSpace
The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country into the …
Latest News & Press Releases - BioSpace
4 天之前 — Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030. Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the …
Pipeline - BioSpace
2024年11月20日 — Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can …
Novartis, Ono Latest to Announce Billion-Dollar M&A Deals
2024年3月5日 — Pictured: A collage of biopharma M&A/ Nicole Bean for BioSpace. After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and …